Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Amyotrophic Lateral Sclerosis Treatment & Management

  • Author: Carmel Armon, MD, MSc, MHS; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
 
Updated: Mar 23, 2016
 

Approach Considerations

Treatment of amyotrophic lateral sclerosis (ALS) may be divided broadly into the following[19, 164, 165] :

  • Patient education
  • Mechanism-specific treatment
  • Adaptive or supportive treatment

Patient education can be enhanced by referral to multidisciplinary clinics staffed by specialists with special interest in ALS, by educational materials prepared for patients and families by national organizations in the United States[166, 167] and other countries or by individual experts,[19] and by patient participation in local support groups.

Next

Inpatient and Outpatient Care

Outpatient care

Most of the care of patients with ALS may be delivered in the outpatient setting. Often, guidance can be provided by a neurologist, physiatrist, or palliative care physician with special interest in the disease.

Multidisciplinary clinics can provide "one-stop shopping", allowing patients to receive all assessments and recommendations in the course of a single visit; most of these clinics provide a combination of on-site and off-site services. In the United States, Muscular Dystrophy Association/ALS centers and ALS Association certified centers have been established at several major medical centers, and in the United Kingdom, the Motor Neurone Disease Association has a network of 18 accredited Motor Neuron Disease Care and Research Centres.

While multidisciplinary clinics are a highly effective method of delivering care to patients with ALS, this approach may not be available in all venues, because of inadequate patient volume or, in some cases, insufficient philanthropic support. Some patients find full-day assessments exhausting; for them, more frequent, but shorter, visits are more acceptable.

In other models of care, the multidisciplinary team works in the community and visits the patient at home or care is provided through a local hospice team. Primary care providers have an important role and in some settings may be able to coordinate all of the care for a patient with ALS.

Inpatient care

Inpatient care may be needed temporarily for patients with ALS who decompensate in the outpatient setting (eg, because of pneumonia). Hospitalization may also be necessary for patients who reach critical ventilatory failure without having appropriate ventilatory support in place or without having made end-of-life decisions (advance directives) declining such ventilatory support and electing for comfort measures instead.

Previous
Next

Riluzole

The glutamate pathway antagonist riluzole (Rilutek) is the only medication that has shown efficacy in extending life in ALS. Compared with placebo, riluzole may prolong median tracheostomy-free survival by 2-3 months in patients younger than 75 years with definite or probable ALS who have had the disease for less than 5 years and who have a forced vital capacity (FVC) of greater than 60%.[168]

Studies

This conclusion is based on 2 double-blinded, randomized, placebo-controlled clinical trials.[33, 34] A third clinical trial, in patients who were ineligible to participate in the second pivotal clinical trial, did not show efficacy, possibly due to low power (small number of patients included relative to the magnitude of the possible effect).[34, 169] A fourth clinical trial, conducted in Japan, did not show efficacy; details of the study’s results have not been published in the English literature.[170, 171]

A Cochrane review that pooled data from the first 3 clinical trials reported that the addition of data from the third trial, which included patients who were older and more seriously affected, reduced the overall treatment effect seen in the first 2 trials.[168] Nevertheless, evidence of benefit from riluzole remained statistically significant.

Subsequent reports have claimed greater efficacy for riluzole in clinical practice than in the clinical trial. However, the relevance of these claims has been challenged[172] because the reports pit class IV evidence against class I evidence, which is contrary to the usual evidence-based approach used to judge treatment efficacy.

Prognosis

Patients with ALS who have depression, frontotemporal dementia (FTD), or a milder level of frontal impairment are now recognized as less likely to accept treatment recommendations and have a poorer prognosis. However, although failure to accept riluzole treatment is a risk factor for poor survival, it is not the cause. Furthermore, registries in place since before the introduction of riluzole show no overall extension of survival of patients with ALS.

Adverse effects

The principal clinical side effects some patients with riluzole may experience are stomach upset and asthenia (lack of energy). These problems resolve if the medication is discontinued.

Cases of interstitial lung disease, some of them severe, have been reported in patients treated with riluzole; many of these cases have proved to be hypersensitivity pneumonitis. If respiratory symptoms such as dry cough and/or dyspnea develop, chest radiography should be performed, and if findings suggest interstitial lung disease or hypersensitivity pneumonitis (eg, bilateral diffuse lung opacities), riluzole should be discontinued immediately. In most reported cases, respiratory symptoms resolved after drug discontinuation and symptomatic treatment.

Aminotransferase

Some patients on riluzole develop abnormal liver function test results or neutropenia. Serum levels of aminotransferases, including alanine aminotransferase (ALT), should be measured before and during riluzole therapy, with ALT levels being evaluated every month during the first 3 months of treatment, every 3 months during the remainder of the first year, and periodically thereafter.

Serum ALT levels should be evaluated more frequently in patients who develop elevations. Treatment should be discontinued if ALT levels reach 5 times the upper limit of normal or higher or if clinical jaundice develops.

Previous
Next

American Academy of Neurology Guideline

In October 2009, the American Academy of Neurology (AAN) published a 2-part, evidence-based Practice Parameter update about the care of patients with ALS.[2, 3] These publications updated the 1999 evidence-based practice parameter.[164]

NIV, PEG, and riluzole

The chief findings of the practice parameter are that for extending life or slowing disease progression, the evidence is best for use of noninvasive ventilation (NIV), percutaneous endoscopic gastrostomy (PEG), and riluzole. The authors comment that these treatments are often underutilized and recommend that they should be offered to patients, in the case of riluzole, or considered by the physician, in the case of NIV and PEG.

The median extension of life by riluzole in placebo-controlled studies was 2-3 months. The median extension of life by NIV or PEG may be approximately 6 months, provided the treatments are applied early and adhered to. The efficacy of NIV is supported by a randomized, controlled trial.[173]

Multidisciplinary care

The authors also recommend that referral to a multidisciplinary clinic should be considered for managing patients with ALS. Such clinics can optimize healthcare delivery, prolong survival, and enhance quality of life.

Botulinum toxin

In patients with sialorrhea that is refractory to treatment with standard medications, botulinum toxin B injection of the salivary glands should be considered. Alternatively, low-dose radiation therapy to the salivary glands may be considered.

Botulinum toxin for ALS carries a manufacturer's warning regarding possible spread of the toxin to ventilatory muscles (leading to exacerbation of ventilatory failure) or bulbar muscles (exacerbating their weakness). The risk of these adverse effects tilts the balance in terms of safety toward salivary gland irradiation, except in patients with exceptional ventilatory and bulbar reserves.

Dextromethorphan and quinidine

Finally, the guideline recommends that dextromethorphan and quinidine be considered for pseudobulbar affect. A combination of these 2 agents (Nuedexta) is approved by the FDA for this indication.

Clinician and patient summaries, as follow, are available on the AAN website:

Previous
Next

Treatment of Symptoms

Limb stiffness

Limb stiffness can be treated with the antispasticity agents baclofen (Lioresal) and tizanidine (Zanaflex). Baclofen can be started at 10 mg/day and titrated up to 10 mg 3 times per day. If adequate efficacy is not attained at a lower dose, baclofen can be titrated to double that dose, if tolerated. Tizanidine can be started at 1 mg 3 times daily and titrated upward, if tolerated, to as high as 8 mg 3 times daily.

The chief risks of both of these agents are that they induce drowsiness in some patients and that relief of spasticity may result in unpredictable loss of tone and falls. Starting at a low dose permits determination of the patient’s tolerance of the medication, before titration to an effective dose.

Intrathecal baclofen may be considered in slowly progressive, upper motor neuron (UMN) ̶ predominant patients with ALS or in patients with primary lateral sclerosis (PLS), who do not respond adequately to oral treatments.

Sialorrhea

Antisialorrhea treatments include the following:

  • Anticholinergics
  • Sympathomimetics
  • Botulinum toxin type B (potentially hazardous)
  • Salivary gland irradiation

Anticholinergics such as amitriptyline (25-50 mg at bedtime) and trihexyphenidyl (Artane; 0.5-2 mg as needed) may be administered as tolerated. A scopolamine patch may work in patients who have not attained adequate relief from oral anticholinergics. Sympathomimetics such as pseudoephedrine may be tried if tolerated; 30-60 mg may be administered as needed or 120-240 mg/day of the extended-release formulations may be used.

The efficacy of injections of botulinum toxin type B (2500 U) into the salivary glands has been reported in a small, double-blinded, placebo-controlled trial[174] , but there is a concern that the toxin could spread to bulbar or respiratory muscles, and there is a manufacturer’s warning to that effect. Salivary gland irradiation (7.5 Gy) was found to effective in a case series with a standardized outcome measure[175] and does not carry the same risk as botulinum toxin.

Thickened secretions

Mucolytics such as guaifenesin may be used to thin thickened secretions, although removal of secretions may require mechanical suction devices. Adequate hydration and humidification of room air may prove helpful and are recommended.

Depression and anxiety

For treatment of depression, selective serotonin reuptake inhibitors (SSRIs), such as citalopram 10-40 mg/day, work best. If the desired benefit is not achieved with one agent in this class, another may be tried.

For anxiety, lorazepam is commonly used (0.5-1 mg prn). Careful titration is required, as benzodiazepines have the potential to cause respiratory depression.

Pain

Pain may occur in patients with ALS as a secondary consequence of immobility, loss of muscle protection of joints, loss of muscle and fat padding of bony prominences, and overexerted muscles. Nonpharmacologic measures to protect bony prominences (cushions and appropriate bed padding) and support overexerted muscles (neck support, trunk support) should be pursued. Range-of-motion exercises should be employed to prevent frozen shoulders.

If pain develops, its causes need to be assessed and appropriate treatment initiated. Often, nonsteroidal anti-inflammatory drugs (NSAIDs) suffice. If needed, they should be prescribed on a regular schedule.

If stronger analgesics are required, tramadol (Ultram), ketorolac (Toradol), morphine (immediate or extended release), or a fentanyl patch may be considered. (Respiratory depression may occur with opiates.) Careful titration, starting with low doses, is needed. Patients must be assured that they will not be in pain as a result of the disease or its secondary consequences.

A combination of dextromethorphan and quinidine (Nuedexta) has shown efficacy in ameliorating involuntary laughter and crying (the expression of pseudobulbar affect).[176, 177] It has FDA approval for this indication.

Cramps

Cramps are difficult to treat. Quinine sulfate was used in the past; the recommended dose for nocturnal cramps was 200-300 or 324 mg at bedtime. However, quinine does not have FDA approval for this indication, its efficacy compared with placebo has not been well established, and there is a concern regarding its potential adverse cardiac effects. Quinine sulfate is contraindicated in patients with a prolonged QT segment, and has many interactions with other drugs. Its clearance is reduced in patients with renal failure.

Other agents that may be tried for treatment of cramps are benzodiazepines, antispasticity agents, and anticonvulsants (eg, gabapentin, carbamazepine, phenytoin). These agents have not been tested for this indication in controlled studies or approved for it, and their efficacy is uncertain.

Incontinence

Urinary urgency may be treated with tolderodine (Detrol). However, the effectiveness of this agent for incontinence may be limited when the incontinence is due to weakening of the muscles of the pelvic floor.

Sleeping problems

When patients complain of sleeping difficulties, the first step is to determine whether these are due to ventilatory failure; this can be accomplished through overnight polysomnography. In some cases the integrity of sleep can be restored just by introducing noninvasive ventilatory support, which usually consists of bilevel positive airway pressure (often with a backup rate). Adjunctive medications may be considered, but the clinician must bear in mind that some drugs may suppress the respiratory drive (hence the need to initiate noninvasive ventilatory support first).

Loss of appetite

Appetite tends to be reduced as ALS progresses. The following reasons have been imputed:

A full stomach makes it harder to breathe

Breakdown of muscle releases amino acids that produce a false sense of satiety

Metabolism of carbohydrates produces CO2, which requires breathing effort to clear

Reduced activity requires less energy intake

Appetite tends to be lost with reduced intake, creating a vicious circle

Nutritional consultation is advised. Frequent small meals, foods rich in fat and protein, and sometimes a feeding gastrostomy are needed. When initiating supplemental feedings in a patient who has not been nourished adequately, attention should be given to ventilatory support, as the patient may be too weak to blow off the extra CO2 or to breathe against a full stomach.

Previous
Next

Ventilatory Support

Noninvasive ventilatory support has been shown to improve patients’ quality of life and to extend life when applied as patients begin to experience the early effects of ventilatory failure, including sleep disruption. Noninvasive ventilatory support is probably more effective than all other treatments for prolonging life in ALS patients.

Overnight polysomnography may identify disruption of the contiguity of sleep, one of the early consequences of ventilatory failure that may precede frank apneas, hypopneas, or nocturnal oxygen desaturation.

  • Invasive ventilatory support, requiring tracheostomy, may be considered in the following cases:
  • Patients who present with respiratory failure and who are otherwise largely neurologically intact
  • Patients who want to be kept alive using long-term invasive ventilatory support as their disease progresses
  • Patients in whom secretions cannot be managed, and who therefore cannot benefit from noninvasive ventilatory support (this occurs very rarely)
Previous
Next

Dietary Considerations

The patient’s appetite tends to decline as the disease progresses, and his/her ability to swallow may become impaired. Consultations with a dietician or nutritionist and with a speech therapist may be requested to help the patient compensate for these losses. Dietary supplements may be used to assure adequate caloric intake.

Placement of a feeding gastrostomy may be considered in patients who cannot maintain adequate caloric intake as a result of swallowing difficulties and who have an FVC of greater than 50% of predicted. A gastrostomy can be placed even in patients with an FVC of less than 50% of predicted, but it requires extra care – usually anesthesiology presence. Consultation with a gastroenterologist or surgeon may be requested if PEG placement is being considered.

Previous
Next

Activity Restriction

Initially, no activity restriction is necessary. Indeed, early in the course of ALS, encourage patients to continue routine activities. However, patients should not overexert themselves to the point of fatigue or pain.

Patients should maintain a regular exercise regimen if their degree of weakness allows. They need to realize, however, that their muscle reserve will diminish before overt sustained weakness appears, which means that in most cases they should avoid extreme endurance exercises (repetitions). Patients with slowly progressive disease will be able to tolerate exercise and benefit from it more than patients with rapidly progressive disease.

The chief goals of activity are as follows:

  • Maintenance of range of motion of all joints
  • Prevention of painful contractures
  • Maintenance of tone and strength of muscles not yet or minimally affected by the disease
  • Maintenance or improvement of cardiovascular health, mood, and energy level (this can be accomplished with low-impact exercise)

As the disease progresses, patients may become unstable and at risk of falls and may need to be counseled to use assistive devices or to not transfer without appropriate support. If they reach a point at which they cannot manage a vehicle safely, including in emergencies, they need to be counseled to stop driving or have modifications made to the car so that they are able to drive safely.

In the United States, some states require mandatory reporting by practitioners to the Department of Motor Vehicle Affairs, and some require disabled patients to pass a driving assessment if they have modifications made to their car (eg, hand controls). In the United Kingdom, any medical condition likely to last more than 3 months requires reporting to the Driver and Vehicle Licensing Agency by the patient.

Previous
Next

Alternative Therapies

Many patients with ALS elect to try alternative therapies. If not unsafe or exorbitantly priced, these treatments may be a reasonable approach to giving patients a sense of some control, may confer on them a feeling of calm, and may thus be of benefit, in subjective terms. Since most, if not all, alternative therapies have not been tested against placebo controls, physicians cannot provide blanket recommendations but may be able to be supportive, if circumstances permit, of specific patient choices.

When alternative therapies impose a great burden on patients, in terms of cost or time commitment, they should be avoided. Since 2009, the ALS Untangled group of investigators, who are members of the North American ALS Research Group or the World Federation of Neurology (WFN) ALS Research Group, has evaluated several claims of efficacy of specific alternative therapies (to slow the course of ALS) and shown them to lack adequate foundation.

Previous
Next

Deterrence and Prevention

Smoking is the only established environmental risk factor for ALS.[52, 54] Smoking avoidance may result in a decrease in the age-specific incidence of the disease. However, this presumptive benefit may be attenuated if lower mortality from other smoking-related diseases (eg, cancer, cardiovascular diseases, stroke) results in more patients surviving to be at risk for ALS in each age bracket. As the population lives to older ages (in which age-specific incidence of ALS is higher), the crude incidence of ALS may increase.

Individuals with a gene for familial ALS may benefit from genetic counseling if they wish to minimize the risk of transmitting the gene to the next generation.

Previous
Next

Informing Patients of the Diagnosis

Doing this properly requires time, motivation, adequate staff, and preparation. The American Academy of Neurology (AAN) 1999 Practice Parameter[164] provided the following suggestions for breaking the news of a diagnosis of ALS to a patient, based on a review of literature pertaining to other diseases:

  • Give the diagnosis to the patient and discuss its implications; respect the cultural and social background of the patient in the communication process by asking whether the patient wishes to receive information or prefers that the information be communicated to a family member
  • Always give the diagnosis in person, never by telephone
  • Provide printed materials about the disease, as well as contact information for advocacy associations (providing a written summary or audiotape summarizing what has been discussed was suggested, but this author believes that this option needs to be exercised primarily in the absence of adequate printed material)
  • Avoid withholding the diagnosis, providing insufficient information, delivering information callously, or taking away or failing to provide hope

In this era of readily available information on the Internet, provision of the diagnosis will generate independent activity on the part of patients, families and friends to educate themselves about the disease. Thus, it is helpful if clinicians point patients and the families to those resources that they feel will serve this purpose best, to serve as the starting point (see Patient Education).

The 2009 AAN update to the 1999 practice parameter[2] refers to a 6-step protocol, described by the acronym SPIKES, that was designed for delivering bad news to patients with cancer.[178] The following is summarized from Appendix e-1[2] :

  • Setting - Establish the appropriate setting
  • Perception - Determine the needs and the perception of the patient
  • Invitation - Request an invitation to give the news
  • Knowledge - Provide knowledge (information) to the patient
  • Explore/Empathic - Explore the patient’s feelings with empathic responses
  • Summarize/Strategy - Summarize and form a strategy with the patient with which to go forward

The SPIKES protocol has several advantages and may be further improved by the following 3 measures. First, it is important that relevant family members be present when the patient is informed about the diagnosis, so that the patient is not the one who has to inform them and answer their questions. They can support the patient, and the neurologist can inform and support them directly.

Second, it is very helpful to schedule an early follow-up visit to answer questions that will arise and inform/update family members who were not present when the diagnosis was given. Many patients and families will not remember most of what they are told when they hear the diagnosis for the first time, as they will be in shock. The shock may be less if they have anticipated the bad news, but it cannot be avoided completely. The greater the perceived shock, the more the focus should be on support and discussing the next steps, including the follow-up visit.

Third, it is helpful to have a handout summarizing the information presented in the clinic. The handout should provide links to appropriate Web sites, as many patients will want to take an active role in educating themselves with the use of these resources.

The patient and his/her family may want to tarry a while after the visit. It is helpful to have a nonphysician staff member available to support them and to reinforce the immediate next steps.

Previous
Next

Patient Support and Advice

Support groups are available to patients in many communities. Burnout of the primary caregiver needs to be anticipated and avoided by assuring that the primary caregiver is not the only caregiver.

Clinical trials

Patients with ALS may wish to help with the search for treatments for the disease through participation in clinical trials. They should be encouraged to focus on trials that have been listed with the ALS Association, the Muscular Dystrophy Association (MDA), and ClinicalTrials.gov, which is a registry of federally and privately supported clinical trials conducted in the United States and around the world.

Off-label pharmaceuticals

Patients often request prescription of pharmaceuticals for off-label use in the hope of slowing disease progression. Since double-blinded, placebo-controlled studies to date have shown that all such pharmaceuticals either made patients worse or had no benefit, this practice should be avoided.

Government benefits

In the United States, patients are eligible for Social Security and Medicare benefits once they are diagnosed with ALS, without the waiting period required of other patients with chronic diseases. Patients should be advised to apply early.

Since September 2008, ALS has been considered a service-connected condition for US veterans, and they are eligible for care and benefits.[179] Eligible patients should be advised to apply early. Volunteers from local branches of veterans’ organizations may be able to assist in preparing the application and moving it rapidly through the approval process.

End-of-life considerations

End-of-life issues may be discussed and clarified early. However, this may not work well for some patients. The physician should be aware of the individual state or national laws that regulate these issues; encourage, if appropriate for the patient, completion of advance directives; and document the patient’s preferences in the medical records, whether or not formal advance directives have been written.

Resource access

For patients with limited access to home-based resources, social service professionals may be able to assist with placement. Local branches of advocacy organizations (the ALS Association of America and the Muscular Dystrophy Association) may be excellent sources of information on what resources are available locally.

Legal affairs

Patients will have decreasing ability to sign documents or to mobilize themselves for taking care of personal affairs. Some may benefit from legal advice. The earlier they do so, the better, but they should be allowed to recover first from the initial shock of the diagnosis.

Loss of independence

All patients will become at risk for falls as ALS progresses; they should be informed of this and cautioned gently. Most patients tend to sustain several falls before they relinquish the independent activities that led to them.

All patients will become unable to drive as their disease progresses. They need to be alerted when this draws close. Most are gracious about quitting before their driving results in injury. Some states require mandatory reporting by practitioners to the Department of Motor Vehicle Affairs. In the United Kingdom, patients are obliged to inform the Driver and Vehicle Licensing Agency.

Previous
Next

Consultations

Consultants are best used within the multidisciplinary model based on patients’ preferences and need to complement the range of services that the patients’ primary care providers and primary neurologists, palliative care physicians, or physiatrists can provide directly. The following consultations may prove helpful:

  • Physical and occupational therapists help the patient adapt to loss of function, provide exercises to maximize existing function and ameliorate spasticity, identify safety concerns and advise how to address them, and help patients to select and learn to use assistive devices, including, as the disease advances, a customized wheelchair
  • A speech therapist can advise on adaptation to swallowing difficulties and, as speech fails, on the use of communication devices
  • A respiratory therapist can assist with learning to use noninvasive ventilation support and, if needed, advise on secretion management, suctioning equipment, and selection of a cough assistive device
  • A dietician or nutritionist evaluates caloric intake; advises how to optimize it, particularly if intake is declining; and may be able to provide guidance regarding nutritional supplementation
  • A pulmonologist, if needed, assesses for tracheostomy and manages the ventilator, tracheostomy, and complications (such as infections) if this treatment is selected
  • A gastroenterologist or general surgeon advises and performs PEG placement and advises on its care and maintenance
  • Visiting nurses assess patients’ in-home needs and help quantify the need for and time the introduction of personal care assistants (home healthcare aides) and home-based therapies
  • Hospice service provides the framework for in-home end-of-life care or helps with alternative arrangements
  • Spiritual (religious) services, if elected by patients, usually connect with the resource of their choice

While many patients and families may benefit from referral to a psychiatrist, psychologist, or counselor, patients may be most likely to use these resources if they have already done so prior to disease onset or if these options are offered within the multidisciplinary model of care.

Previous
Next

Long-Term Monitoring

Patients are best cared for in a designated ALS center. Many mechanical aids can help them to overcome disabilities. A patient’s length of survival and quality of life are enhanced by night-time breathing assistance early in the course of the disease and by aggressive application of alternate feeding options to ensure good nutrition once swallowing becomes difficult.[180]

The 2009 AAN practice parameter guideline reviewed available evidence to help maximize the care and quality of life of patients with ALS.[2, 3] The recommendations can be summarized as follows:

  • Riluzole should be offered to all patients with ALS to slow disease progression
  • Enteral nutrition via PEG should be considered to stabilize body weight in patients with impaired oral intake
  • PEG placement when FVC is still greater than 50% predicted minimizes the risk of insertion
  • PEG placement probably prolongs survival to some degree
  • NIV should be offered to treat respiratory insufficiency in order to prolong survival and slow the decline of FVC
  • NIV may be considered at the earliest sign of nocturnal hypoventilation or respiratory insufficiency
  • Mechanical insufflation/exsufflation may be considered to clear secretions in patients with reduced peak cough flow, particularly during an acute lower respiratory infection
  • Creatine and high-dose vitamin E should not be used
Previous
 
 
Contributor Information and Disclosures
Author

Carmel Armon, MD, MSc, MHS Chair, Department of Neurology, Assaf Harofeh Medical Center, Tel Aviv University Sackler Faculty of Medicine, Israel

Carmel Armon, MD, MSc, MHS is a member of the following medical societies: American Academy of Neurology, Massachusetts Medical Society, American Academy of Sleep Medicine, American Stroke Association, American Association of Neuromuscular and Electrodiagnostic Medicine, American Clinical Neurophysiology Society, American College of Physicians, American Epilepsy Society, American Medical Association, American Neurological Association, Sigma Xi

Disclosure: Received research grant from: Neuronix Ltd, Yoqnea'm, Israel.

Chief Editor

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Acknowledgements

Neil A Busis, MD Chief, Division of Neurology, Department of Medicine, Head, Clinical Neurophysiology Laboratory, University of Pittsburgh Medical Center-Shadyside

Neil A Busis, MD is a member of the following medical societies: American Academy of Neurology and American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec. 1(5):293-9. [Medline].

  2. [Guideline] Miller RG, Jackson CE, Kasarskis EJ et al. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009. 73:1218-1226. [Medline]. [Full Text].

  3. [Guideline] Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009 Oct 13. 73(15):1227-1233. [Medline]. [Full Text].

  4. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011 Oct 11. 7(11):639-49. [Medline].

  5. King SJ, Duke MM, O'Connor BA. Living with amyotrophic lateral sclerosis/motor neurone disease (ALS/MND): decision-making about 'ongoing change and adaptation'. J Clin Nurs. 2009 Mar. 18(5):745-54. [Medline].

  6. Eisen A. Amyotrophic lateral sclerosis: A 40-year personal perspective. J Clin Neurosci. 2009 Apr. 16(4):505-12. [Medline].

  7. Phukan J, Hardiman O. The management of amyotrophic lateral sclerosis. J Neurol. 2009 Feb. 256(2):176-86. [Medline].

  8. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009 Feb 3. 4:3. [Medline]. [Full Text].

  9. Brooks BR. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol. 2009 Jan. 65 Suppl 1:S17-23. [Medline].

  10. Al-Chalabi A, Fang F, Hanby MF, Leigh PN, Shaw CE, Ye W, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010 Dec. 81(12):1324-6. [Medline]. [Full Text].

  11. Hudson AJ. Clinical Neurology. The motor neuron diseases and related disorders. 1996. Vol. 4: 11-14.

  12. Kanouchi T, Ohkubo T, Yokota T. Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation?. J Neurol Neurosurg Psychiatry. 2012 Jul. 83(7):739-45. [Medline]. [Full Text].

  13. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011 Oct 20. 72(2):257-68. [Medline]. [Full Text].

  14. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011 Oct 20. 72(2):245-56. [Medline]. [Full Text].

  15. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009 Apr 16. 62(1):42-52. [Medline]. [Full Text].

  16. Armon C. What is ALS?. Bedlack RS, Mitsumoto H, Eds. Amyotrophic Lateral Sclerosis: A Patient Care Guide for Clinicians. New York: Demos Medical Publishing; 2012. 1-23.

  17. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009 Sep 8. 73(10):805-11. [Medline]. [Full Text].

  18. Armon C. Epidemiology of ALS/MND. Shaw P and Strong M, eds. Motor Neuron Disorders. Elsevier Sciences: 2003. 167-206.

  19. Armon C. ALS 1996 and Beyond: New Hopes and Challenges. A manual for patients, families and friends. Fourth Edition. California: Published by the LLU Department of Neurology, Loma Linda; 2007. [Full Text].

  20. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998 Dec. 51(6):1546-54. [Medline].

  21. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry. 1994 Apr. 57(4):416-8. [Medline].

  22. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009 Sep 8. 73(10):805-11. [Medline]. [Full Text].

  23. Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology. 2009 Mar 24. 72(12):1087-94. [Medline]. [Full Text].

  24. Almeida V, de Carvalho M, Scotto M, Pinto S, Pinto A, Ohana B, et al. Primary lateral sclerosis: predicting functional outcome. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Mar. 14(2):141-5. [Medline].

  25. Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010 Mar 1. 48(5):629-41. [Medline].

  26. Strong MJ. Progress in clinical neurosciences: the evidence for ALS as a multisystems disorder of limited phenotypic expression. Can J Neurol Sci. 2001 Nov. 28(4):283-98. [Medline].

  27. Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry. 2005 Aug. 76(8):1046-57. [Medline]. [Full Text].

  28. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009 Jan. 65 Suppl 1:S3-9. [Medline].

  29. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993 Mar 4. 362(6415):59-62. [Medline].

  30. Shaw PJ, Ince PG, Falkous G, Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol. 1995 Oct. 38(4):691-5. [Medline].

  31. Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology. 2004 May 25. 62(10):1758-65. [Medline].

  32. Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008 Jun. 9(3):177-83. [Medline].

  33. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994 Mar 3. 330(9):585-91. [Medline].

  34. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996 May 25. 347(9013):1425-31. [Medline].

  35. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006 Oct 6. 314(5796):130-3. [Medline].

  36. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006 Dec 22. 351(3):602-11. [Medline].

  37. Tan CF, Eguchi H, Tagawa A, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol. 2007 May. 113(5):535-42. [Medline].

  38. Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007 May. 61(5):427-34. [Medline].

  39. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008 Mar 21. 319(5870):1668-72. [Medline].

  40. Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008 May. 40(5):572-4. [Medline].

  41. Van Deerlin VM, Leverenz JB, Bekris LM, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008 May. 7(5):409-16. [Medline].

  42. Yokoseki A, Shiga A, Tan CF, et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol. 2008 Apr. 63(4):538-42. [Medline].

  43. Rutherford NJ, Zhang YJ, Baker M, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008 Sep 19. 4(9):e1000193. [Medline].

  44. Del Bo R, Ghezzi S, Corti S, et al. TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. Eur J Neurol. 2009 Jun. 16(6):727-32. [Medline].

  45. Hasegawa M, Arai T, Akiyama H, et al. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain. 2007 May. 130:1386-94. [Medline].

  46. Schwab C, Arai T, Hasegawa M, Akiyama H, Yu S, McGeer PL. TDP-43 pathology in familial British dementia. Acta Neuropathol. 2009 Mar 13. [Medline].

  47. Geser F, Martinez-Lage M, Robinson J, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol. 2009 Feb. 66(2):180-9. [Medline].

  48. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009 Feb 27. 323(5918):1205-8. [Medline].

  49. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009 Feb 27. 323(5918):1208-11. [Medline].

  50. Simpson CL, Lemmens R, Miskiewicz K, Broom WJ, Hansen VK, van Vught PW, et al. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum Mol Genet. 2009 Feb 1. 18(3):472-81. [Medline]. [Full Text].

  51. Padhi AK, Kumar H, Vasaikar SV, Jayaram B, Gomes J. Mechanisms of loss of functions of human angiogenin variants implicated in amyotrophic lateral sclerosis. PLoS One. 2012. 7(2):e32479. [Medline]. [Full Text].

  52. Armon C. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology. 2003 Jul-Aug. 22(4):217-28. [Medline].

  53. Armon C. Acquired nucleic acid changes may trigger sporadic amyotrophic lateral sclerosis. Muscle Nerve. 2005 Sep. 32(3):373-7. [Medline].

  54. Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology. November 17, 2009. 73 (20):1693-1698. [Medline]. [Full Text].

  55. de Jong SW, Huisman MH, Sutedja NA, van der Kooi AJ, de Visser M, Schelhaas HJ, et al. Smoking, alcohol consumption, and the risk of amyotrophic lateral sclerosis: a population-based study. Am J Epidemiol. 2012 Aug 1. 176(3):233-9. [Medline].

  56. Esclaire F, Kisby G, Spencer P, Milne J, Lesort M, Hugon J. The Guam cycad toxin methylazoxymethanol damages neuronal DNA and modulates tau mRNA expression and excitotoxicity. Exp Neurol. 1999 Jan. 155(1):11-21. [Medline].

  57. Kisby GE, Standley M, Park T, et al. Proteomic analysis of the genotoxicant methylazoxymethanol (MAM)-induced changes in the developing cerebellum. J Proteome Res. 2006 Oct. 5(10):2656-65. [Medline].

  58. Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology. 2007 May 8. 68(19):1571-5. [Medline].

  59. Körner S, Kollewe K, Fahlbusch M, et al. Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis. Muscle Nerve. 2011 May. 43(5):636-42. [Medline].

  60. Armon C. From clues to mechanisms: understanding ALS initiation and spread. Neurology. 2008 Sep 16. 71(12):872-3. [Medline].

  61. Frank SA. Evolution in health and medicine Sackler colloquium: Somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration. Proc Natl Acad Sci U S A. 2010 Jan 26. 107 Suppl 1:1725-30. [Medline]. [Full Text].

  62. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011 Oct 20. 72(2):245-56. [Medline]. [Full Text].

  63. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011 Oct 20. 72(2):257-68. [Medline]. [Full Text].

  64. Cooper-Knock J, Hewitt C, Highley JR, Brockington A, Milano A, Man S, et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 2012 Mar. 135:751-64. [Medline]. [Full Text].

  65. Chiò A, Borghero G, Restagno G, Mora G, Drepper C, Traynor BJ, et al. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain. 2012 Mar. 135:784-93. [Medline]. [Full Text].

  66. Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012 Mar. 11(3):232-40. [Medline]. [Full Text].

  67. Stewart H, Rutherford NJ, Briemberg H, Krieger C, Cashman N, Fabros M, et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol. 2012 Mar. 123(3):409-17. [Medline]. [Full Text].

  68. Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology. 2009 Mar 24. 72(12):1087-94. [Medline].

  69. Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered. 2011. 71(4):281-8. [Medline].

  70. Hanby MF, Scott KM, Scotton W, Wijesekera L, Mole T, Ellis CE, et al. The risk to relatives of patients with sporadic amyotrophic lateral sclerosis. Brain. 2011 Dec. 134:3454-7. [Medline]. [Full Text].

  71. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006 Sep. 7(9):710-23. [Medline].

  72. Fogh I, Rijsdijk F, Andersen PM, Sham PC, Knight J, Neale B, et al. Age at onset in sod1-mediated amyotrophic lateral sclerosis shows familiality. Neurogenetics. 2007 Aug. 8(3):235-6. [Medline].

  73. Ahmeti KB, Ajroud-Driss S, Al-Chalabi A, Andersen PM, Armstrong J, et al. The Algen Consortium. Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. Neurobiol Aging. 2013 Jan. 34(1):357.e7-19. [Medline].

  74. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know?. Nat Rev Neurol. 2011 Oct 11. 7(11):603-15. [Medline].

  75. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011 Nov. 7(11):616-30. [Medline].

  76. Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012 Aug 23. 488(7412):499-503. [Medline]. [Full Text].

  77. Andersen PM. Amyotrophic lateral sclerosis genetics with Mendelian inheritance. Brown RH Jr, Swash M and Pasinelli P, eds. Amyotrophic Lateral Sclerosis. 2nd edition. Informa healthcare; 2006. 187-207.

  78. Saeed M, Yang Y, Deng HX, et al. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology. 2009 May 12. 72(19):1634-9. [Medline].

  79. Saito Y, Yokota T, Mitani T, et al. Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model. J Biol Chem. 2005 Dec 30. 280(52):42826-30. [Medline].

  80. Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012 Sep. 124(3):339-52. [Medline].

  81. Arai T, Mackenzie IR, Hasegawa M, et al. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 2009 Feb. 117(2):125-36. [Medline].

  82. Morita M, Al-Chalabi A, Andersen PM, Hosler B, Sapp P, Englund E, et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology. 2006 Mar 28. 66(6):839-44. [Medline].

  83. Vance C, Al-Chalabi A, Ruddy D, Smith BN, Hu X, Sreedharan J, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain. 2006 Apr. 129:868-76. [Medline].

  84. van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009 Oct. 41(10):1083-7. [Medline].

  85. Shatunov A, Mok K, Newhouse S, Weale ME, Smith B, Vance C. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol. 2010 Oct. 9(10):986-94. [Medline].

  86. Laaksovirta H, Peuralinna T, Schymick JC, Scholz SW, Lai SL, Myllykangas L. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol. 2010 Oct. 9(10):978-85. [Medline].

  87. Smith BN, Newhouse S, Shatunov A, Vance C, Topp S, Johnson L, et al. The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet. 2013 Jan. 21(1):102-8. [Medline]. [Full Text].

  88. Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, et al. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol. 2011 Dec. 122(6):691-702. [Medline].

  89. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011 Aug 21. 477(7363):211-5. [Medline]. [Full Text].

  90. Majoor-Krakauer D, Ottman R, Johnson WG, Rowland LP. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology. 1994 Oct. 44(10):1872-7. [Medline].

  91. Fallis BA, Hardiman O. Aggregation of neurodegenerative disease in ALS kindreds. Amyotroph Lateral Scler. 2009 Apr. 10(2):95-8. [Medline].

  92. Cruz DC, Nelson LM, McGuire V, Longstreth WT Jr. Physical trauma and family history of neurodegenerative diseases in amyotrophic lateral sclerosis: a population-based case-control study. Neuroepidemiology. 1999. 18(2):101-10. [Medline].

  93. Nelson LM, McGuire V, Longstreth WT Jr, Matkin C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol. 2000 Jan 15. 151(2):156-63. [Medline].

  94. Kamel F, Umbach DM, Munsat TL, Shefner JM, Sandler DP. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology. 1999. 18(4):194-202. [Medline].

  95. Gallo V, Bueno-De-Mesquita HB, Vermeulen R, Andersen PM, Kyrozis A, Linseisen J. Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort. Ann Neurol. 2009 Apr. 65(4):378-85. [Medline].

  96. Sutedja NA, Veldink JH, Fischer K, Kromhout H, Wokke JH, Huisman MH. Lifetime occupation, education, smoking, and risk of ALS. Neurology. 2007 Oct 9. 69(15):1508-14. [Medline].

  97. Weisskopf MG, O'Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology. 2005 Jan 11. 64(1):32-7. [Medline].

  98. Horner RD, Kamins KG, Feussner JR, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology. 2003 Sep 23. 61(6):742-9. [Medline].

  99. Armon C. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology. 2004 Mar 23. 62(6):1027; author reply 1027-9. [Medline].

  100. Armon C. Excess incidence of ALS in young Gulf War veterans. Neurology. 2004 Nov 23. 63(10):1986-7; author reply 1986-7. [Medline].

  101. Coffman CJ, Horner RD, Grambow SC, Lindquist J. Estimating the occurrence of amyotrophic lateral sclerosis among Gulf War (1990-1991) veterans using capture-recapture methods. Neuroepidemiology. 2005. 24(3):141-50. [Medline].

  102. Horner RD, Grambow SC, Coffman CJ, et al. Amyotrophic lateral sclerosis among 1991 Gulf War veterans: evidence for a time-limited outbreak. Neuroepidemiology. 2008. 31(1):28-32. [Medline].

  103. Barth SK, Kang HK, Bullman TA, Wallin MT. Neurological mortality among U.S. veterans of the Persian Gulf War: 13-year follow-up. Am J Ind Med. 2009 Sep. 52(9):663-70. [Medline].

  104. Sutedja NA, Veldink JH, Fischer K, Kromhout H, Heederik D, Huisman MH, et al. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler. 2009 Oct-Dec. 10(5-6):302-9. [Medline].

  105. Popat RA, Van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of amyotrophic lateral sclerosis. Neuroepidemiology. 2006. 27(3):117-21. [Medline].

  106. Beghi E, Logroscino G, Chiò A, Hardiman O, Millul A, Mitchell D, et al. Amyotrophic lateral sclerosis, physical exercise, trauma and sports: results of a population-based pilot case-control study. Amyotroph Lateral Scler. 2010 May 3. 11(3):289-92. [Medline]. [Full Text].

  107. Chiò A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain. 2005 Mar. 128:472-6. [Medline].

  108. Belli S, Vanacore N. Proportionate mortality of Italian soccer players: is amyotrophic lateral sclerosis an occupational disease?. Eur J Epidemiol. 2005. 20(3):237-42. [Medline].

  109. Armon C. Sports and trauma in amyotrophic lateral sclerosis revisited. J Neurol Sci. 2007 Nov 15. 262(1-2):45-53. [Medline].

  110. Chio A, Traynor BJ, Swingler R, eet al. Amyotrophic lateral sclerosis and soccer: a different epidemiological approach strengthen the previous findings. J Neurol Sci. 2008 Jun 15. 269(1-2):187-8; author reply 188-9. [Medline].

  111. Belli S, Vanacore N. Sports and amyotrophic lateral sclerosis. J Neurol Sci. 2008 Jun 15. 269(1-2):191; author reply 191-2. [Medline].

  112. Armon C. Amyotrophic lateral sclerosis and soccer: a different epidemiological approach strengthen the previous findings. J Neurol Sci. 2008. 269:188-189 (author reply).

  113. Armon C. Response to Belli and Vanacore. J Neurol Sci. 2008. 269:191192 (author reply).

  114. Chio A, Calvo A, Dossena M, Ghiglione P, Mutani R, Mora G. ALS in Italian professional soccer players: the risk is still present and could be soccer-specific. Amyotroph Lateral Scler. 2009 Aug. 10(4):205-9. [Medline].

  115. McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2010 Sep. 69(9):918-29. [Medline]. [Full Text].

  116. Appel SH, Cwik VA, Day JW. Trauma, TDP-43, and amyotrophic lateral sclerosis. Muscle Nerve. 2010 Dec. 42(6):851-2. [Medline].

  117. Bedlack RS, Genge A, Amato AA, Shaibani A, Jackson CE, Kissel JT, et al. Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29. J Neuropathol Exp Neurol. 2011 Jan. 70(1):96-7; author reply 98-100. [Medline].

  118. Armon C, Miller RG. Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29. J Neuropathol Exp Neurol. 2011 Jan. 70(1):97-8; author reply 98-100. [Medline].

  119. Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative causes of death among retired National Football League players. Neurology. 2012 Nov 6. 79(19):1970-4. [Medline].

  120. Armon C, Nelson LM. Is head trauma a risk factor for amyotrophic lateral sclerosis? An evidence based review. Amyotroph Lateral Scler. 2012 Jun. 13(4):351-6. [Medline].

  121. Peters TL, Fang F, Weibull CE, Sandler DP, Kamel F, Ye W. Severe head injury and amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013 May. 14(4):267-72. [Medline].

  122. Kurland LT, Radhakrishnan K, Smith GE, Armon C, Nemetz PN. Mechanical trauma as a risk factor in classic amyotrophic lateral sclerosis: lack of epidemiologic evidence. J Neurol Sci. 1992 Dec. 113(2):133-43. [Medline].

  123. Savica R, Parisi JE, Wold LE, Josephs KA, Ahlskog JE. High school football and risk of neurodegeneration: a community-based study. Mayo Clin Proc. 2012. 87:335-340.

  124. Wicks P, Ganesalingham J, Collin C, Prevett M, Leigh NP, Al-Chalabi A. Three soccer playing friends with simultaneous amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007 Jun. 8(3):177-9. [Medline].

  125. Whiting MG. Toxicity of Cycads: A Literature Review. Economic Botany. 1963. 68:270-302.

  126. Borenstein AR, Mortimer JA, Schellenberg GD, Galasko D. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2009 Feb 3. 72(5):473, 476; author reply 475-6. [Medline].

  127. Steele JC, McGeer PL. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology. 2008 May 20. 70(21):1984-90. [Medline].

  128. Borenstein AR, Mortimer JA, Schofield E, et al. Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam. Neurology. 2007 May 22. 68(21):1764-71. [Medline].

  129. Cox PA, Banack SA, Murch SJ. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci U S A. 2003 Nov 11. 100(23):13380-3. [Medline].

  130. Khabazian I. Isolation of various forms of sterol B-D-glucoside from the seed of Cycas circinalis: neurotoxicity and implications for the ALS-parkinsonian dementia complex. J Neurochem. 2002. 82:516-528.

  131. Chiò A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009 Feb 24. 72(8):725-31. [Medline].

  132. Alonso A, Logroscino G, Jick SS, Hernán MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009 Jun. 16(6):745-51. [Medline].

  133. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006 Dec. 253(12):1642-3. [Medline].

  134. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006 Dec. 253(12):1642-3. [Medline].

  135. Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007 Mar 27. 68(13):1002-7. [Medline].

  136. Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study. Neurology. 2009 May 12. 72(19):1640-5. [Medline].

  137. Rojas-Garcia R, Scott KM, Roche JC, Scotton W, Martin N, Janssen A, et al. No evidence for a large difference in ALS frequency in populations of African and European origin: a population based study in inner city London. Amyotroph Lateral Scler. 2012 Jan. 13(1):66-8. [Medline].

  138. Sabel CE, Boyle PJ, Löytönen M, et al. Spatial clustering of amyotrophic lateral sclerosis in Finland at place of birth and place of death. Am J Epidemiol. 2003 May 15. 157(10):898-905. [Medline].

  139. Manjaly ZR, Scott KM, Abhinav K, Wijesekera L, Ganesalingam J, Goldstein LH, et al. The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotroph Lateral Scler. 2010 Oct. 11(5):439-42. [Medline].

  140. Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006 Jan 24. 66(2):265-7. [Medline].

  141. Turner MR, Scaber J, Goodfellow JA, Lord ME, Marsden R, Talbot K. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J Neurol Sci. 2010 Jul 15. 294(1-2):81-5. [Medline].

  142. Murphy J, Henry R, Lomen-Hoerth C. Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol. 2007 Mar. 64(3):330-4. [Medline].

  143. Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012 Jan. 83(1):102-8. [Medline].

  144. Elamin M, Phukan J, Bede P, Jordan N, Byrne S, Pender N, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. 2011 Apr 5. 76(14):1263-9. [Medline].

  145. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009 Oct-Dec. 10(5-6):310-23. [Medline]. [Full Text].

  146. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006. 66:265-267.

  147. Armon C, Moses D. Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials. J Neurol Sci. 1998 Oct. 160 Suppl 1:S37-41. [Medline].

  148. Armon C, Graves MC, Moses D, Forté DK, Sepulveda L, Darby SM, et al. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2000 Jun. 23(6):874-82. [Medline].

  149. Armon C, Brandstater ME. Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve. 1999 Nov. 22(11):1571-5. [Medline].

  150. Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol. 2006 Nov. 253(11):1428-36. [Medline].

  151. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012 Mar. 135:847-52. [Medline]. [Full Text].

  152. Kim WK, Liu X, Sandner J, Pasmantier M, Andrews J, Rowland LP, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology. 2009 Nov 17. 73(20):1686-92. [Medline]. [Full Text].

  153. Armon C, Schultz JD. Preferences of patients with ALS for accurate prognostic information. Presented at the annual meeting of the International Alliance of Motor Neuron Disease Associations. Philadelphia. December 2004. [Full Text].

  154. Armon C. ALS 1996 and Beyond: New Hopes and Challenges. A Manual for Patients, Families and Friends. Loma Linda University Department of Neurology, Loma Linda, California. Fourth Edition. 2007.

  155. Isaacs JD, Dean AF, Shaw CE, Al-Chalabi A, Mills KR, Leigh PN. Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder?. J Neurol Neurosurg Psychiatry. 2007 Jul. 78(7):750-3. [Medline]. [Full Text].

  156. Byrne S, Elamin M, Bede P, Hardiman O. Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2012 Apr. 83(4):365-7. [Medline].

  157. Byrne S, Bede P, Elamin M, Kenna K, Lynch C, McLaughlin R, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 May. 12(3):157-9. [Medline].

  158. de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008 Mar. 119(3):497-503. [Medline].

  159. Bromberg MB, Swoboda KJ, Lawson VH. Counting motor units in chronic motor neuropathies. Exp Neurol. 2003 Nov. 184 Suppl 1:S53-7. [Medline].

  160. Armon C, Brandstater ME. Motor unit number estimate-based rates of progression of ALS predict patient survival. Muscle Nerve. 1999 Nov. 22(11):1571-5. [Medline].

  161. Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol Sci. 1997 Oct. 152 Suppl 1:S1-9. [Medline].

  162. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31. 169(1-2):13-21. [Medline].

  163. Instructions for completing the ALSFRS-R. (ALS Functional Rating Scale). ALS Connection. [Full Text].

  164. [Guideline] Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology. 1999 Apr 22. 52(7):1311-23. [Medline]. [Full Text].

  165. Bedlack RS, Mitsumoto H, Eds. Amyotrophic Lateral Sclerosis: A Patient Care Guide for Clinicians. New York: Demos Medical Publishing; 2012.

  166. Amyotrophic Lateral Sclerosis Association. Available at http://www.alsa.org.

  167. Muscular Dystrophy Association. Available at http://als.mdausa.org/.

  168. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007 Jan 24. CD001447. [Medline].

  169. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002 May. 249(5):609-15. [Medline].

  170. Yanagisawa N, Tashiro K, Tohgi H, et al. Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan. Igakuno Ayumi. 1997. 182:851-866. [Article in Japanese].

  171. Yanagisawa N, Shindo M. [Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)]. Rinsho Shinkeigaku. 1996 Dec. 36(12):1329-30. [Medline].

  172. Armon C, Guiloff RJ, Bedlack R. Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Sep. 3(3):109-12. [Medline].

  173. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006. 5:140-147. [Medline].

  174. Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009 Feb. 39(2):137-43. [Medline].

  175. Neppelberg E, Haugen DF, Thorsen L, Tysnes OB. Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis. Eur J Neurol. 2007 Dec. 14(12):1373-7. [Medline].

  176. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004 Oct 26. 63(8):1364-70. [Medline].

  177. Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010 Nov. 68(5):693-702. [Medline].

  178. Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist. 2000. 5(4):302-11. [Medline].

  179. VA Secretary Establishes ALS as a Presumptive Compensable Illness. September 23, 2008. VA Secretary Establishes ALS as a Presumptive Compensable Illness. September 23, 2008. [Full Text].

  180. Lo Coco D, Marchese S, Pesco MC, La Bella V, Piccoli F, Lo Coco A. Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology. 2006 Sep 12. 67(5):761-5. [Medline].

  181. Harding A. PET scans distinguish ALS patients from healthy controls. Reuters Health Information. March 11, 2014. [Full Text].

  182. Migliore L, Coppede F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res. 2008 Oct 31. [Medline].

  183. Valdmanis PN, Rouleau GA. Genetics of familial amyotrophic lateral sclerosis. Neurology. 2008 Jan 8. 70(2):144-52. [Medline].

  184. Van Laere K, Vanhee A, Verschueren J, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014 Mar 10. [Medline].

  185. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994 Jul. 124 Suppl:96-107. [Medline].

  186. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008 Mar. 119 (3):497-503. [Medline].

  187. Chiò A, Battistini S, Calvo A, Caponnetto C, Conforti FL, Corbo M, et al. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry. 2014 May. 85 (5):478-85. [Medline].

  188. Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A. 2011 Jan 4. 108 (1):260-5. [Medline].

  189. Zu T, Liu Y, Bañez-Coronel M, Reid T, Pletnikova O, Lewis J, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013 Dec 17. 110 (51):E4968-77. [Medline].

  190. Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014 Nov. 13 (11):1108-13. [Medline].

  191. Fournier CN, Gearing M, Upadhyayula SR, Klein M, Glass JD. Head injury does not alter disease progression or neuropathologic outcomes in ALS. Neurology. 2015 Apr 28. 84 (17):1788-95. [Medline].

  192. Woolley SC, Strong MJ. Frontotemporal Dysfunction and Dementia in Amyotrophic Lateral Sclerosis. Neurol Clin. 2015 Nov. 33 (4):787-805. [Medline].

 
Previous
Next
 
The 4 regions or levels of the body. Bulbar (muscles of the face, mouth, and throat); cervical (muscles of the back of the head and the neck, the shoulders and upper back, and the upper extremities); thoracic (muscles of the chest and abdomen and the middle portion of the spinal muscles); lumbosacral (muscles of the lower back, groin, and lower extremities).
The genetic/environmental/age- and time-dependent interactions hypothesis for amyotrophic lateral sclerosis (ALS). Risk factors operate upstream to a putative biochemical transformation (likely an acquired nucleic acid or protein change), which causes the appearance of altered proteins or nucleic acids or abnormal quantities of normal proteins or nucleid acids. These agents spread within the motor system and cause the downstream disintegration of the motor system and the downstream biochemical, histologic, and clinical consequences of ALS. (Adapted from Armon C. What is ALS? In: Amyotrophic Lateral Sclerosis: A Patient Care Guide for Clinicians. Bedlack RS, Mitsumoto H, Eds. Demos Medical Publishing, New York, 2012:1-23)
Muscle in nerve disease. Image courtesy of Dr. Friedlander, Associate Professor and Chair of Pathology at Kansas City University of Medicine and Biosciences.
Table 1. Familial Forms of ALS [74, 75, 76]
Gene Locus Protein Inheritance
SOD1



(ALS1)



21q22.11 Superoxide dismutase 1 (SOD1) AD*
ALS2 2q33 Alsin (ALS2) Juvenile/AR**
ALS3 18q21 Unknown AD
ALS4 9q34 SETX Juvenile/AD
ALSS 15q15 SPG11 Juvenile/AR
FUS (ALS6) 16p11.2 FUS AD
ALS7 20ptel-p13 Unknown AD
ALS8 20q13.3 VABP AD
ALS9 14q11.2 Angiogenin (ANG) AD
TARDBP (ALS10) 1p36.2 TAR DNA-binding protein (TARDBP) AD
ALS11 6q21 FIG4 AD
ALS12 10p13 OPTN AD; AR
ALS13 12q24 ATXN2 AD
ALSX Xp11 UBQLN2 X-linked
C9orf72 (ALS-FTD) 9q21-22 C9ORF72 AD
ALS-FTD 9p13.3 SIGMAR1 AD; Juvenile/AR
PFL1 17p13.2 Profilin 1 AD
*AD–autosomal dominant; **AR—autosomal recessive
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.